NRAS and melanoma: In the multivariate analysis, statistical significance was associated with anti-PD-1 used as the first-line therapy (p < 0.001), <3 metastatic sites (p < 0.01), site of melanoma onset (head and neck were better than trunk and lower limbs, and upper limbs were better than lower limbs), lower platelet count (p = 0.03), and presence of NRAS mutation (p = 0.05).